The Mycobacterium Bovis BCG Prime-Rv0577 DNA Boost Vaccination Induces a Durable Th1 Immune Response in Mice.

Dongqing Gu,Wei Chen,Youjun Mi,Xueli Gong,Tao Luo,Lang Bao
DOI: https://doi.org/10.1093/abbs/gmw010
IF: 3.7
2016-01-01
Acta Biochimica et Biophysica Sinica
Abstract:Tuberculosis remains a major global health problem and effective vaccines are urgently needed. In this study, we used the combined DNA- and protein-based vaccines of immunodominant antigen Rv0577 to boost BCG and evaluated their immunogenicity in BALB/c mice. Our data suggest that the booster vaccine may substantially enhance the immunogenicity of BCG and strengthen both CD4+ T cell-mediated Th1 and CD8+ T cell-mediated cytolytic responses. Compared with the protein-based vaccine, the DNA-based vaccine can induce more durable Th1 immune response, characterized by high levels of antibody response, proliferation response, percentages of CD4+/CD8+ and cytokine secretion in antigen-stimulated splenocyte cultures. In conclusion, we for the first time, developed a protein- and plasmid DNA-based booster vaccine based on Rv0577. Our findings suggest that antigen Rv0577-based DNA vaccine is immunogenic and can efficiently boost BCG, which could be helpful in the design of an efficient vaccination strategy against TB.
What problem does this paper attempt to address?